Tradr 2X Long ACHR Daily ETF ARCX 深 沪
等待开盘 08-06 09:30:00 美东时间
17.86
-0.520
-2.83%
华盛通- 最 高18.8299
- 今 开18.53
- 成交量 12.66万股
- 最 低 17.1305
- 昨 收 18.38
- 总市值 964.44万
- 52周最高 33.07
- 市盈率 静 24.49
- 换手率 23.45%
- 52周最低 15.45
- 委 比 23.08%
- 总股本 54.00万
- 历史最高 33.07
- 量 比 0.68
- 振 幅 9.25%
- 历史最低 13.51
- 每 手 1
- 风险率 3.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tradr Prepares Five Leveraged Single-Stock ETF Launches
First-to-market ETFs on CoreWeave, AST SpaceMobile, Constellation Energy, GE Vernova & NuScale Power NEW YORK, July 9, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophis...
07-10 01:11
Quantum Volatility? Tradr's New ETFs QUBX, RGTU Are Built for It, Says Matt Markiewicz
"It's the volatility that attracts traders," Matt Markiewicz, head of Product and Capital Markets at Tradr, told Benzinga.
06-25 01:42
Tradr Launches Leveraged ETFs on Quantum Computing Inc. (QUBT) and Rigetti Computing (RGTI)
QUBX, a first-to-market fund, and RGTU offer 2X daily exposure on disruptive quantum computing stocks NEW YORK, June 24, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for soph...
06-24 18:45
Tradr Readies Two More Quantum Single-Stock ETF Launches
Upcoming listing of QUBX & RGTU bolsters firm's leveraged strategies on high-flying quantum computing names NEW YORK, June 18, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed fo...
06-19 04:29
Tradr Launches First Ever Leveraged ETFs on Archer Aviation and Upstart Holdings
ARCX and UPSX offer 2X Daily Exposure to two captivating growth stories NEW YORK, June 10, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and profes...
06-10 18:45
Arcutis Enrolls First Child in INTEGUMENT-INFANT Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis
Arcutis Biotherapeutics, Inc. has initiated a Phase 2 study, INTEGUMENT-INFANT, to assess the safety and tolerability of ZORYVE (roflumilast) cream 0.05% in infants aged 3 months to 24 months with atopic dermatitis (AD). AD affects approximately 9.6 million children in the U.S., with 60% of cases developing symptoms within the first year of life. ZORYVE, a highly potent PDE4 inhibitor, is being evaluated as a potential long-term treatment for inf...
06-10 12:00
